Trial
NCT04058145
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
Merck Sharp & Dohme LLC; AperiSys, Inc
Condition
Head and Neck Cancer
Intervention
AMD3100
Why stopped
Funding Withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-07